MedCap acquires and develops profitable, market-leading niche companies in the Nordic life science industry that have the potential to grow internationally. The group conducts operations in two areas: MedTech and Specialty Pharma.
During the fiscal year 1 January – 31 December 2019, the MedCap group exhibited annual sales of approximately SEK 757 million and EBITDA of SEK 140 million, and had approximately 270 employees. The group is listed on the Small Cap list of Nasdaq Stockholm.